Menu
ncarol.com
  • Home
  • Business
  • Health
  • Real Estate
  • Books
  • Education
  • Financial
  • Transportation
  • Arts
ncarol.com

Isosceles Pharmaceuticals, Inc. Appoints William D. Humphries as its Chief Executive Officer
ncarol.com/10114932

Trending...
  • Georgia Misses the Mark Again on Sports Betting, While Offshore Sites Cash In
  • Her Magic Mushroom Memoir Launches as a Binge-Worthy Novel-to-Podcast Experience
  • How LIB's Temperature & Humidity Chamber & Walk-in Chamber Warranty Delivered Real Uptime
WILMINGTON, N.C., May 5, 2021 /PRNewswire/ -- Isosceles Pharmaceuticals Inc. a biotechnology company dedicated to developing, commercializing, and marketing innovative non-opioid products for the treatment of mild to moderate pain and inflammatory diseases, today announced the appointment of William D. Humphries as its Chief Executive Officer. Mr. Humphries is a highly accomplished executive leader in the pharmaceutical industry with a proven track record leading several global pharmaceutical companies.

"We are excited to welcome Bill for the role of Chief Executive Officer," said Tim Wright, Chairman of Isosceles Board of Directors. "His extensive background in the pharmaceutical industry will provide invaluable leadership as Isosceles achieves its strategic growth milestones."

Most recently, Mr. Humphries served as President of Ortho Dermatologics, a subsidiary of  Bausch Health Companies. He has also held global executive leadership positions at Merz North America, GlaxoSmithKline, Stiefel, and Allergan.

"I would like to thank Tim and the Isosceles team for welcoming me to company," said Mr. Humphries, Chief Executive Officer of Isosceles. "I was attracted to Isosceles by their focus on the pursuit of innovative solutions for safe, novel non-opioid pain relief and the passion the team has for delivering these important products to the market. I look forward to leveraging my experience to accelerate the company's development plans and lead Isosceles as it unlocks its full potential."

More on ncarol.com
  • "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience
  • New Slotozilla Project Explores What Happens When the World Goes Silent
  • The Two Faces of Charles D. Braun: How the Novel, Posthumously Yours, Came to Life
  • Counseling Center of New Smyrna Beach Expands Affordable Mental Health Services for Volusia County
  • Marty the Martian Farmer: A Retro Sci-Fi Comedy with a Cosmic Twist

Mr. Humphries currently serves as Chairman of the Board at Clearside Biomedical, Chairman of the North Carolina State University Global Luxury Management Board, is a member of the Board at Aclaris Therapeutics, and a member of the Board at Strata Skin Sciences. He received his MBA from Pepperdine University and completed his undergraduate studies at Bucknell University.

About Isosceles Pharmaceuticals, Inc.

Isosceles Pharmaceuticals is a preclinical stage biotechnology and medical device company focused on the delivery of drug master file backed synthetic cannabinoids for their anti-inflammatory and pain relief properties. The Company's proprietary formulations coupled with unique delivery platforms provide high bioavailability via parenteral and transdermal routes.

Investor Contact
Brett Lanier
[email protected]

SOURCE Isosceles Pharmaceuticals, Inc.

Related Links

www.isoscelespharma.com
Filed Under: Business

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • SecureMaine 2025 is this October 8th in Portland, Maine
  • John Thomas calls for unity and prayer after tragic loss
  • Where the Miami Dolphins Stand After Week 1
  • Which NFL Teams Can Rebound from Week 1? OddsTrader Breaks Down the Biggest Questions
  • Apellix Deploys Breakthrough Spray-Painting Drones into Live Service Limited Beta Program Open for Advanced Contractors
  • Coming Up on the Podcast "Financial Freedom with Tom Hegna" Larry and Judy Poole
  • DivX Unveils New Educational Blog Series to Simplify MKV to MP4 Video Conversion
  • CCHR: For Prevention, Families Deserve Truth From NIH Study on Psychiatric Drugs
  • United Mitochondrial Disease Foundation Announces 2025 Energy For Life Walk – Charlotte
  • Sheets.Market Brings Professional Financial Model Templates to Entrepreneurs and Startups
  • Webinar Announcement: Investing in the European Defense Sector—How the New Era of Uncertainty Is Redefining Investment Strategies
  • AEVIGRA (AEIA) Analysis Reveals $350 Billion Counterfeit Market Driving Luxury Sector Toward Blockchain Authentication
  • Her Magic Mushroom Memoir Launches as a Binge-Worthy Novel-to-Podcast Experience
  • Century Fasteners de Mexico Hires Saúl Pedraza Gómez as Regional Sales Manager in Mexico
  • Georgia Misses the Mark Again on Sports Betting, While Offshore Sites Cash In
  • $40 Price Target for $NRXP in H. C. Wainright Analyst Report on Leader in $3 Billion Suicidal Depression Market with Superior NRX 100 Drug Therapy
  • Nashville International Chopin Piano Competition Partners with Crimson Global Academy to Support Excellence in Education
  • Entrinsicon 2025 Returns to Raleigh, Showcases AI and Data Innovation
  • AHRFD Releases Market Analysis: Cryptocurrency Market's Institutional Transformation Accelerating
  • Ubleu Crypto Group Analyzes European Digital Asset Market Opportunities Amid Regulatory Evolution
_catLbl0 _catLbl1

Popular on ncarol.com

  • $5 - $20 Million in Sales for 2026; $25 - $40 Million for 2027 Projected with NASA Agreements; New MOU Signed to Improve Solar Tech in Space - 538
  • The Office of Count Jonathan of Aquitaine Establishes Centre for Education and Diplomacy - 164
  • Dr. Sanju P. Jose Highlights Expertise in Periodontics and Implant Dentistry - 134
  • Assent Joins AWS ISV Accelerate Program - 127
  • Ubleu Crypto Group Achieves FinCEN Registration and Colorado Incorporation, Accelerating U.S. Market Entry - 115
  • Sustainably Made in New York: MOO Vodka and Cayuga Clear Expand Statewide Distribution - 105
  • Vancouver Community College Forms Strategic Partnership with PebblePad - 103
  • Sober.Buzz Adds Second Podcast, "Spreading the Good BUZZ" Guest List Grows, Numbers Continue Growing Globally, All While Josh and Heidi Tied the Knot
  • Iterators Named Preferred Accessibility Testing Vendor by MIT
  • RUNWAY Milestones 1995-2025 Global Influence

Similar on ncarol.com

  • Youth Take the Lead: Kopp Foundation for Diabetes Hosts "By Youth, For Youth, With T1D" Gala on October 8 at Blue Bell Country Club
  • "Leading From Day One: The Essential Guide for New Supervisors" Draws from 25+ Years of International Management Experience
  • New Slotozilla Project Explores What Happens When the World Goes Silent
  • Albuquerque's Z-CoiL Footwear Brings All-American Family Business Story to Shark Tank Season Premiere
  • Unicorp and BH Group Select Chasing Creative—Palm Coast Agency—to Lead Growth Marketing for The Ritz-Carlton Residences, Hammock Dunes
  • SecureMaine 2025 is this October 8th in Portland, Maine
  • Where the Miami Dolphins Stand After Week 1
  • Which NFL Teams Can Rebound from Week 1? OddsTrader Breaks Down the Biggest Questions
  • Sheets.Market Brings Professional Financial Model Templates to Entrepreneurs and Startups
  • Webinar Announcement: Investing in the European Defense Sector—How the New Era of Uncertainty Is Redefining Investment Strategies
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute